Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy

Area of Science:

• Stem cell therapy
• Neuroscience
• Gene therapy

Background:

• Pluripotent stem cell (PSC) therapies offer promise for neurodegenerative diseases.
• Tumorigenesis from undifferentiated PSCs is a significant safety concern.
• Targeted elimination of proliferative cells while preserving neurons is crucial for safe transplantation.

Purpose of the Study:

• To evaluate thymidine kinase-based suicide genes and nucleoside analogs as safety switches for PSC-based neural transplants.
• To identify the most effective and selective suicide gene system and drug combination.

Main Methods:

• Tested various thymidine kinase variants, including humanized SR39 (SR39h).
• Investigated promoter control (ubiquitous vs. cell cycle-dependent Ki67) for SR39h expression.
• Assessed the efficacy of six nucleoside analogs (including penciclovir, ganciclovir, acyclovir) in inducing cell death.
• Evaluated in vivo tumor prevention with selected nucleoside analogs.

Main Results:

• The SR39h thymidine kinase variant showed high sensitivity to suicide induction.
• Cell cycle-dependent SR39h expression under the Ki67 promoter prevented ganciclovir-induced death in post-mitotic neurons.
• Penciclovir (PCV) demonstrated efficacy comparable to ganciclovir (GCV) with lower toxicity.
• In vivo, PCV and GCV (40 mg/kg/day) prevented tumor formation, while acyclovir (ACV) did not.

Conclusions:

• SR39h combined with a cell cycle-dependent promoter is an efficient and selective safety switch for neural transplants.
• Penciclovir and ganciclovir are effective inducers of cell death in this system.
• Penciclovir's low toxicity makes it a potentially preferred alternative to ganciclovir for clinical applications.